Adaptimmune Therapeutics ADAPY
OTC ADAPY
$0.03 +0.00 (+0.00%)
At close: Oct 21, 2026 · 4:00 PM EDT

Adaptimmune Therapeutics PLC (ADAPY) Non Operating Interest Expenses (2017 - 2025)

Updated

Adaptimmune Therapeutics' Non Operating Interest Expenses came in at $962,000 for Q2 2025, up 82.9% from $526,000 a year earlier but down 48.9% from the prior quarter.

Analysis

Adaptimmune Therapeutics PLC (ADAPY) Non Operating Interest Expenses (2017 - 2025) Analysis & Trends

Over the trailing twelve months to Jun 30, 2025, Adaptimmune Therapeutics reported Non Operating Interest Expenses of $5.67 million; for FY2024, it came in at $3.35 million.

  • The five-year range for quarterly Non Operating Interest Expenses is $526,000 (Q2 2024) to $1.88 million (Q1 2025).
  • Business Quant data shows ADAPY's Non Operating Interest Expenses at $1.88 million (Q1 2025), $1.71 million (Q4 2024) and $1.11 million (Q3 2024) in the three quarters before Q2 2025.
Peer Set

Peer Comparison

Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 962,000.00
Mar 31, 2025 1.88 Mn
Dec 31, 2024 1.71 Mn
Sep 30, 2024 1.11 Mn
Jun 30, 2024 526,000.00
Sep 30, 2017 8,000.00
Jun 30, 2017 6,000.00
API Access

Adaptimmune Therapeutics PLC Non Operating Interest Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-operating-interest-expenses&ticker=ADAPY&period=max&api_key=YOUR_API_KEY